You are here: Industry Insights > IMPACT

News List

Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S. prnasia
March 11, 2021
Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 in the United States.
FDA Grants Fast Track Designation to Padeliporfin ImPACT americanpharmaceuticalreview
January 21, 2021
Steba biotech announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for padeliporfin ImPACT for the treatment of adult patients with low-grade and unifocal high-grade Upper Tract Urothelial Cancer (UTUC).
Global Cord Blood Corporation Provides Update on Impact of Coronavirus prnasia
February 16, 2020
On December 31, 2019, the Wuhan Municipal Health Commission first reported the appearance of 2019-nCoV in the city.
Cryoport, Celularity Enter Supply Chain Partnership contractpharma
April 15, 2019
Celularity to use Cryoport’s temperature controlled logistics solutions...
Tim Freeman's Powder Flow Feature: Exploring the Impact of Particle Size on Bulk Powder Properties Tim Freeman
December 01, 2017
There are many variables that influence powder behaviour.
IMPACT Received IMP4297 Chinese IND Approval en-cphi.cn
May 04, 2017
IMPACT Therapeutics, Inc. (IMPACT) announced that CFDA granted approval to its IND application of IMP4297, a potential best-in-class PARP inhibitor, in January 2017.